PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Posttranslational modifications to the intracellular domain of the EGFR are known to regulate EGFR functions; however, modifications to the extracellular domain and their effects remain relatively unexplored. Here, we determined that methylation at R198 and R200 of the EGFR extracellular domain by protein arginine methyltransferase 1 (PRMT1) enhances binding to EGF and subsequent receptor dimerization and signaling activation. In a mouse orthotopic colorectal cancer xenograft model, expression of a methylation-defective EGFR reduced tumor growth. Moreover, increased EGFR methylation sustained signaling activation and cell proliferation in the presence of the therapeutic EGFR monoclonal antibody cetuximab. In colorectal cancer patients, EGFR methylation level also correlated with a higher recurrence rate after cetuximab treatment and reduced overall survival. Together, these data indicate that R198/R200 methylation of the EGFR plays an important role in regulating EGFR functionality and resistance to cetuximab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, methylation at R198 and R200 of the EGFR ECD plays an essential role in regulating EGFR functionality and resistance to cetuximab treatment in CRC patients [145].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [145]
In the citing paper
“In addition, R198/R200 methylation and mutation in the kinase domain of EGFR (V843I) correlated with disease progression in the presence of cetuximab [69].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118 · cited 1×
“Upon binding, cetuximab occludes the EGF-binding site and prevents EGFR from adopting the active conformation required for ligand binding and dimerization (47).”
BackgroundProtein arginine methyltransferases and cancer
Yang, Y., & Bedford, M. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3409 · Cited by 1,083 · cited 1×
“During arginine methylation, PRMTs transfer methyl groups from S-adenosylmethionine (SAM) to the guanidine nitrogen of specific arginine residues on their target proteins, which in turn alter the protein structure, protein-protein interaction, protein localization, and enzyme activity that are critical for various cel…”
BackgroundDe Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H.-S., Leahy, D. J., & Lemmon, M. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00047-9 · Cited by 801
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis
Partridge, E. A., Le Roy, C., Di Guglielmo, G. M., Pawling, J., Cheung, P., Granovsky, M., Nabi, I. R., Wrana, J. L., & Dennis, J. W. (2004) · Science · doi:10.1126/science.1102109 · Cited by 735
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Spatial control of EGF receptor activation by reversible dimerization on living cells
Chung, I., Akita, R., Vandlen, R., Toomre, D., Schlessinger, J., & Mellman, I. (2010) · Nature · doi:10.1038/nature08827 · Cited by 538 · cited 1×
“25 nM, without and with cetuximab, respectively), the affinity of R198/200K mutant EGFR for EGF was critical for the receptor dimerization and subsequent downstream signaling activation (42), we further examined the effect of R198/ R200 methylation on EGFR dimerization.”
BackgroundTejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353
Small Molecule Regulators of Protein Arginine Methyltransferases
Cheng, D., Yadav, N., King, R. W., Swanson, M. S., Weinstein, E. J., & Bedford, M. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401853200 · Cited by 339 · cited 1×
“To rule out the possibility that PRMT1 methylates EGFR during cell lysis, PRMT inhibitor, AMI-1, was added into the cell lysis buffer (32).”
BackgroundAnti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., De Palma, R., Orditura, M., De Vita, F., & Ciardiello, F. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 333
Regulation of Estrogen Rapid Signaling through Arginine Methylation by PRMT1
Le Romancer, M., Treilleux, I., Leconte, N., Robin-Lespinasse, Y., Sentis, S., Bouchekioua-Bouzaghou, K., Goddard, S., Gobert-Gosse, S., & Corbo, L. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.025 · Cited by 324 · cited 1×
“In line with previous reports showing that ERα methylation is a dynamic process, requiring PRMT1 for methylation and JMJD6 arginine demethylase to remove the methylated moiety (56, 57), global proteomic analysis also demonstrated that arginine methylation sites in human cells are regulated dynamically by an unknown Ar…”
BackgroundYoshimatsu, M., Toyokawa, G., Hayami, S., Unoki, M., Tsunoda, T., Field, H. I., Kelly, J. D., Neal, D. E., Maehara, Y., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25366 · Cited by 313 · cited 1×
“Since the discovery of protein arginine methyltransferases (PRMTs), arginine methylation has been implicated in many biological processes and human diseases (9).”
BackgroundThe Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
Sasaki, T., Hiroki, K., & Yamashita, Y. (2013) · BioMed Research International · doi:10.1155/2013/546318 · Cited by 285 · cited 1×
“In addition to their function in normal development, aberrant expression of EGFR is involved in abnormal cell proliferation, reduced apoptosis, cell migration, metastasis, and angiogenesis in cancer patients (1, 2).”
BackgroundFour-jointed Is a Golgi Kinase That Phosphorylates a Subset of Cadherin Domains
Ishikawa, H. O., Takeuchi, H., Haltiwanger, R. S., & Irvine, K. D. (2008) · Science · doi:10.1126/science.1158159 · Cited by 243
Hsu, J.-M., Chen, C.-T., Chou, C.-K., Kuo, H.-P., Li, L.-Y., Lin, C.-Y., Lee, H.-J., Wang, Y.-N., Liu, M., Liao, H.-W., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2158 · Cited by 236 · cited 4×
“Crosstalk between methylation and phosphorylation on intracellular domain regulates downstream signaling activation (3), whereas ubiquitination mediates EGFR stability, trafficking, and signal sustainability (4).”
BackgroundInfluentialSelf-citationMolecular determinants of cetuximab efficacy.
Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234
Arginine methylation controls growth regulation by E2F‐1
Cho, E., Zheng, S., Munro, S., Liu, G., Carr, S. M., Moehlenbrink, J., Lu, Y., Stimson, L., Khan, O., Konietzny, R., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.17 · Cited by 216 · cited 1×
“Interestingly, in colorectal cancer patients, elevated level of PRMT5 was observed and coincided with poor prognosis (59).”
BackgroundActivation and inhibition of erythropoietin receptor function: role of receptor dimerization.
Watowich, S. S., Hilton, D. J., & Lodish, H. F. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3535 · Cited by 201
Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells
Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A., & Lawrence, T. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6389 · Cited by 201 · cited 1×
“Addition of tunicamycin disrupted glycosylation, resulting in the accumulation and retention of immature, unglycosylated EGFR (130 kDa) in the ER/Golgi compartments (31).”
BackgroundWhen ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling
Nguyen, L. K., Kolch, W., & Kholodenko, B. N. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-52 · Cited by 195 · cited 1×
“Crosstalk between methylation and phosphorylation on intracellular domain regulates downstream signaling activation (3), whereas ubiquitination mediates EGFR stability, trafficking, and signal sustainability (4).”
BackgroundProtein arginine methylation of non-histone proteins and its role in diseases
Wei, H., Mundade, R., Lange, K., & Lu, T. (2014) · Cell Cycle · doi:10.4161/cc.27353 · Cited by 190 · cited 1×
“For example, signal transduction, RNA processing, DNA repair, and gene transcription are regulated by arginine methylation (3, 11, 12).”
BackgroundStructural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor
Alvarado, D., Klein, D. E., & Lemmon, M. A. (2010) · Cell · doi:10.1016/j.cell.2010.07.015 · Cited by 189 · cited 1×
“The relative orientation of domains D1 and D2 is conserved in all dimeric EGFR forms, including ligand-free forms from the drosophila EGFR homolog (40, 41), suggesting that our analysis holds for all dimeric conformations.”
BackgroundO-GlcNAc modification, insulin signaling and diabetic complications
Issad, T., Masson, E., & Pagesy, P. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.09.001 · Cited by 170 · cited 2×
“In addition, glycosylation on the extracellular domain of RTK is critical for protein stabilization and subcellular localization (5, 8).”
BackgroundTroiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150
Boisvert, F.-M., Rhie, A., Richard, S., & Doherty, A. J. (2005) · Cell Cycle · doi:10.4161/cc.4.12.2250 · Cited by 143
Organellar Proteomics Reveals Golgi Arginine Dimethylation
Wu, C. C., MacCoss, M. J., Mardones, G., Finnigan, C., Mogelsvang, S., Yates, J. R., & Howell, K. E. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-02-0101 · Cited by 139 · cited 1×
“In mammals, characterization of stacked Golgi fraction using multidimensional protein identification technology suggested that a SAM transporter and methyltransferase may exist in the Golgi proteome isolated from rat liver (55).”
MethodThe PRMT1 gene expression pattern in colon cancer
Mathioudaki, K., Papadokostopoulou, A., Scorilas, A., Xynopoulos, D., Agnanti, N., & Talieri, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604807 · Cited by 133 · cited 1×
“Although high PRMT1 expression has been shown to correlate with colorectal cancer progression (37), its role in colorectal cancer pathophysiology remains obscure.”
BackgroundBlick, S. K. A., & Scott, L. J. (2007) · Drugs · doi:10.2165/00003495-200767170-00008 · Cited by 126
The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation
Yu, Z., Vogel, G., Coulombe, Y., Dubeau, D., Spehalski, E. I., Hébert, J., Ferguson, D. O., Masson, J., & Richard, S. (2011) · Cell Research · doi:10.1038/cr.2011.128 · Cited by 117 · cited 1×
“PRMT1 frequently methylates arginine residues found within glycine-arginine–rich (GAR) domains (29, 30) and generates asymmetric dimethylated arginine.”
BackgroundCustodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 110 · cited 1×
“org Volume 125 Number 12 December 2015 ing activation of HER2 or MET signaling, mutation of PIK3CA and BRAF, or expression status of PTEN, but retrospective analyses revealed inconsistent and controversial findings (16).”
ResultJMJD6 Regulates ERα Methylation on Arginine
Poulard, C., Rambaud, J., Hussein, N., Corbo, L., & Romancer, M. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087982 · Cited by 102
Mao, C., Huang, Y., Yang, Z., Zheng, D., Chen, J., & Tang, J. (2013) · Cancer · doi:10.1002/cncr.27804 · Cited by 99
ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor
Alvarado, D., Klein, D. E., & Lemmon, M. A. (2009) · Nature · doi:10.1038/nature08297 · Cited by 92
Sylvestersen, K. B., Horn, H., Jungmichel, S., Jensen, L. J., & Nielsen, M. L. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o113.032748 · Cited by 91 · cited 1×
“In line with previous reports showing that ERα methylation is a dynamic process, requiring PRMT1 for methylation and JMJD6 arginine demethylase to remove the methylated moiety (56, 57), global proteomic analysis also demonstrated that arginine methylation sites in human cells are regulated dynamically by an unknown Ar…”
BackgroundYalak, G., & Vogel, V. (2012) · Science Signaling · doi:10.1126/scisignal.2003273 · Cited by 86 · cited 1×
“For example, extracellular domain phosphorylation of cadherin protein by intracellular Golgi kinase or ectokinase regulates cell adhesion, cell growth, and cell polarity (6, 7).”
BackgroundScorilas, A., Black, M. H., Talieri, M., & Diamandis, E. P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3807 · Cited by 81 · cited 1×
“Therefore, we deleted the N-terminal hydrophobic signal peptide (29 amino acids) of PRMT1 (34) and examined its subcellular distribution.”
MethodBou-Assaly, W., & Mukherji, S. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2054 · Cited by 66
Emerging roles of post‐translational modifications in signal transduction and angiogenesis
Rahimi, N., & Costello, C. E. (2015) · PROTEOMICS · doi:10.1002/pmic.201400183 · Cited by 63 · cited 1×
“Several arginine methylated RTKs, such as EGFR and VEGFR-2, have been reported (3, 60).”
BackgroundRole of conformational alteration in the epidermal growth factor receptor (EGFR) function
Bishayee, S. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00425-1 · Cited by 56 · cited 3×
“In addition, glycosylation on the extracellular domain of RTK is critical for protein stabilization and subcellular localization (5, 8).”
BackgroundProtein arginine methyltransferases (PRMTs) as therapeutic targets
Cha, B., & Jho, E.-H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.688030 · Cited by 55 · cited 1×
“For example, signal transduction, RNA processing, DNA repair, and gene transcription are regulated by arginine methylation (3, 11, 12).”
Backgroundvan Houdt, W. J., Hoogwater, F. J. H., de Bruijn, M. T., Emmink, B. L., Nijkamp, M. W., Raats, D. A. E., van der Groep, P., van Diest, P., Borel Rinkes, I. H. M., & Kranenburg, O. (2010) · Neoplasia · doi:10.1593/neo.92088 · Cited by 50 · cited 1×
“Interestingly, although some studies have shown that mutant KRAS strongly represses EGF-stimulated activation of ERK phosphorylation in HCT116 and DLD1 colorectal cancer cell lines (51), our data demonstrate that ERK was still activated by EGF stimulation in GEO (G12A) and SKCO1 (G12V) KRAS mutant cell lines (Figure 3…”
ResultHerrmann, F., & Fackelmayer, F. O. (2009) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01266.x · Cited by 48 · cited 1×
“In contrast, exogenous expression of catalytically inactive mutant PRMT1 (VLD-AAA) (36) did not enhance EGFR activation or its downstream signaling, which indicates that upregulation of EGFR signaling by PRMT1 requires its enzymatic activity (Supplemental Figure 3B).”
BackgroundTargeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Patel, R., & Leung, H. Y. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800626148 · Cited by 45 · cited 1×
“In addition to their function in normal development, aberrant expression of EGFR is involved in abnormal cell proliferation, reduced apoptosis, cell migration, metastasis, and angiogenesis in cancer patients (1, 2).”
BackgroundMeßner, I., Cadeddu, G., Huckenbeck, W., Knowles, H. J., Gabbert, H. E., Baldus, S. E., & Schaefer, K. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1319-7 · Cited by 39
Ibar, C., & Orellana, A. (2007) · Plant Physiology · doi:10.1104/pp.107.104679 · Cited by 38 · cited 1×
“These results are consistent with those in plant cells in which SAM is incorporated into the Golgi vesicles and other subcellular compartment as detected by the incorporation of carboxyl [14C]- SAM into these subcellular organelles (54).”
ResultHsieh, Y., Tzeng, C., Chen, M., Chen, P., & Wang, W.-S. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02225.x · Cited by 38 · cited 1×
“It is worthwhile to mention that colorectal cancer patients carrying R497 polymorphism on EGFR extracellular domain 4 exhibit more unfavorable responses to cetuximab than those carrying K497 (52).”
BackgroundFunakoshi, T., Latif, A., & Galsky, M. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.004 · Cited by 36 · cited 1×
“Although EGFR tyrosine kinase inhibitors combined with chemotherapy presented severe toxicity and limited effect (14), the combination of EGFR monoclonal antibody, such as cetuximab and panitumumab, with chemotherapy has shown efficacy in colorectal cancer treatment (15).”
BackgroundMorton, R. F., & Hammond, E. H. (2009) · Journal of Oncology Practice · doi:10.1200/jop.0924603 · Cited by 27
Protein transport into the human ER and related diseases, Sec61-channelopathies
Haßdenteufel, S., Klein, M.-C., Melnyk, A., & Zimmermann, R. (2014) · Biochemistry and Cell Biology · doi:10.1139/bcb-2014-0043 · Cited by 27 · cited 1×
“ER-targeting signal peptide is commonly found at the N-terminus of proteins (33).”
BackgroundAnti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories
Cheng, L., Ren, W., Xie, L., Li, M., Liu, J., Hu, J. Y., Liu, B., & Qian, X. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2489-6 · Cited by 22 · cited 1×
“Currently, rational targeting of molecular signaling pathways that are involved in the etiology of malignancies is one of the most promising strategies in novel anticancer drug development (13).”
BackgroundKrawczyk, P. A., & Kowalski, D. M. (2014) · Współczesna Onkologia · doi:10.5114/wo.2013.38566 · Cited by 21 · cited 1×
“Although EGFR tyrosine kinase inhibitors combined with chemotherapy presented severe toxicity and limited effect (14), the combination of EGFR monoclonal antibody, such as cetuximab and panitumumab, with chemotherapy has shown efficacy in colorectal cancer treatment (15).”
BackgroundSilvestris, N., Tommasi, S., Santini, D., Russo, A. D., Simone, G., Petriella, D., Maiello, E., Tonini, G., & Colucci, G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902870394 · Cited by 16
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabián, P., & Berkovcová, J. (2011) · PubMed · Cited by 2
Cited by
Arginine Methylation: The Coming of Age
Blanc, R. S., & Richard, S. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.11.003 · Cited by 1,054
“Importantly, EGFR methylation levels correlated with higher reappearance rates after therapeutic EGFR monoclonal antibody Cetuximab treatment and reduced survival (Liao et al., 2015).”
BackgroundGenetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“Enhanced EGFR activation can occur via post-translational modifications involving methylation of R198 and R200 by protein arginine methyltransferase 1 (PRMT1), which enhances its binding to EGF and consequent signaling activation, even in the presence of the EGFR inhibitor (Liao et al. 2015).”
BackgroundThe role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
“EGFR mAb resistance in colorectal cancer [203].”
Self-citationThe molecular basis of endothelial cell plasticity
Dejana, E., Hirschi, K. K., & Simons, M. (2017) · Nature Communications · doi:10.1038/ncomms14361 · Cited by 441
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis
Chen, P.-Y., Qin, L., Li, G., Wang, Z., Dahlman, J. E., Malagon-Lopez, J., Gujja, S., Cilfone, N. A., Kauffman, K. J., Sun, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0102-3 · Cited by 346
Metadata
- Authors
- Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., Fang, Y.-F., Lee, H.-J., Lee, H.-H., Tai, S.-K., Yang, M.-H., Morelli, M. P., Sen, M., Ladbury, J. E., Chen, C.-H., Grandis, J. R., Kopetz, S., & Hung, M.-C.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- University of Pittsburgh (US)
- University of Leeds (GB)
- Genomics Research Center, Academia Sinica (TW)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-11-16
- Volume
- 125
- Issue
- 12
- Pages
- 4529-4543
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC4665782
- OpenAlex
- W2176390318
- Cited by
- 155
- References
- 60
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 15 · 2023: 15 · 2022: 12 · 2021: 24 · 2020: 19 · 2019: 16 · 2018: 11 · 2017: 15 · 2016: 8 · 2015: 1
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- King Abdullah University of Science and Technology Repository (King Abdullah University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (CCSG CA 16672, CA 016672, CA109311, R01CA109311, P01CA099031, P30CA016672, P50CA097190, CA 099031)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EGFR, PRMT1, arginine methylation, cetuximab resistance, EGFR signaling, receptor dimerization, colorectal cancer, tumor recurrence, overall survival, monoclonal antibody therapy
- MeSH terms
- Cetuximab, Animals, Colonic Neoplasms, Female, Humans, Methylation, Mice, Nude, Neoplasm Transplantation, Protein-Arginine N-Methyltransferases, Repressor Proteins, Signal Transduction, Cell Line, Tumor, Mice, Heterografts, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.